Potential roles for pharmacists in pharmacogenetics

被引:24
作者
El-Ibiary, Shareen Y. [1 ]
Cheng, Christine [1 ]
Alldredge, Brian [1 ,2 ,3 ]
机构
[1] Univ Calif San Francisco, Dept Clin Pharm, Sch Pharm, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Acad Affairs, Sch Pharm, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Neurol, Sch Med, San Francisco, CA 94143 USA
关键词
pharmacogenetics; pharmacists; research;
D O I
10.1331/JAPhA.2008.07050
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: To highlight areas of pharmacogenetics in which pharmacists may play a role and to describe those roles in the context of specific examples from a major academic medical center. Data sources: Literature search (PubMed) and personal interviews for the University of California at San Francisco case examples. Data synthesis: The field of pharmacogenetics presents a wide range of opportunities for pharmacists. Specific roles for pharmacists are likely to fall within three major domains: developing research methodologies and setting research directions, establishing the value of pharmacogenetic testing in clinical practice, and participating in education and infrastructure development that moves pharmacogenetic technologies toward implementation. Conclusion: As drug therapy experts, pharmacists are in a unique position to push the frontiers of pharmacogenetics in both the research and clinical practice environments.
引用
收藏
页码:E21 / E31
页数:11
相关论文
共 52 条
[1]  
[Anonymous], 2006, CAMPTOSAR
[2]  
BELLINGHAM C, 2003, PHARM J, V270, P508
[3]   Clinical and economic outcomes of pharmacist-managed antiepileptic drug therapy [J].
Bond, C. A. ;
Raehl, Cynthia L. .
PHARMACOTHERAPY, 2006, 26 (10) :1369-1378
[4]   Pharmacogenomics: implications and considerations for pharmacists [J].
Brock, TP ;
Valgus, JM ;
Smith, SR ;
Summers, KM .
PHARMACOGENOMICS, 2003, 4 (03) :321-330
[5]  
Carrico J M, 2000, J Am Pharm Assoc (Wash), V40, P115
[6]   Comparison of an anticoagulation clinic with usual medical care -: Anticoagulation control, patient outcomes, and health care costs [J].
Chiquette, E ;
Amato, MG ;
Bussey, HI .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (15) :1641-1647
[7]   Pharmacogenetics, the next challenge for pharmacy? [J].
Clemerson, Jessica P. ;
Payne, Katherine ;
Bissell, Paul ;
Anderson, Claire .
PHARMACY WORLD & SCIENCE, 2006, 28 (03) :126-130
[8]  
*CRC, 2006, TOX BEN RAT OPT CHEM
[9]   A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].
D'Andrea, G ;
D'Ambrosio, RL ;
Di Perna, P ;
Chetta, M ;
Santacroce, R ;
Brancaccio, V ;
Grandone, E ;
Margaglione, M .
BLOOD, 2005, 105 (02) :645-649
[10]   Optimization of inpatient warfarin therapy: Impact of daily consultation by a pharmacist-managed anticoagulation service [J].
Dager, WE ;
Branch, JM ;
King, JH ;
White, RH ;
Quan, RS ;
Musallam, NA ;
Albertson, TE .
ANNALS OF PHARMACOTHERAPY, 2000, 34 (05) :567-572